Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

spending

Brain cancer glioblastoma

Tension expected as cancer market rises to $150bn-plus

IMS Health report anticipates increased demand for value-based pricing of oncology drugs

- PMLiVE

IMS Health to merge with Quintiles

Will create pharma services firm worth almost $18bn

- PMLiVE

Novel drugs and rare diseases drive US prescription drug spend

But increased competition and cost-cutting measures forced price concessions

- PMLiVE

Under pressure

Six inexorable forces shaping our industry's evolution

- PMLiVE

Learning from forecasting’s past

How previous eras will shape the pharma forecaster of the future

- PMLiVE

China to relax pricing curbs from June

Reports suggest medicine sales could reach $185bn in the region by 2018

- PMLiVE

Global medicines spend to reach $1.3trn by 2018

IMS report suggests end of the ‘patent cliff’

- PMLiVE

Breast cancer drug market set to double in 10 years

New entrants will join market leaders Roche, Novartis and AstraZeneca

- PMLiVE

IMS Health pays €385m for Cegedim businesses

Market research firm takes over information solutions and CRM services

- PMLiVE

Smaller companies driving innovation in pharma

IMS Health says specialty medicines are creating a level playing field

- PMLiVE

A tailored approach to key account management

IMS Health on why a one-size-fits-all model won't work for pharma

Mobile app formulary and cloud hosting platform launched

IMS Health stakes its claim in mHealth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links